Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation

INTRODUCTION: Rivaroxaban is one of the most commonly used non-vitamin K antagonists for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual exposures exist for Asian and non-Asian populations, and dose selection is different for Japanese and non-Japanese...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao-Qin, Zhang, Yu-Fei, Ding, Hong-Yan, Yan, Ming-Ming, Zhong, Ming-Kang, Ma, Chun-Lai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171211/
https://www.ncbi.nlm.nih.gov/pubmed/36691239
http://dx.doi.org/10.1136/bmjopen-2021-058378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171211/
https://www.ncbi.nlm.nih.gov/pubmed/36691239
http://dx.doi.org/10.1136/bmjopen-2021-058378

Ejemplares similares